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Abstract
Background Impaired cerebrovascular reactivity in adult traumatic brain injury (TBI) is known to be associated with poor
outcome. However, there has yet to be an analysis of the association between the comprehensively assessed intracranial hyper-
tension therapeutic intensity level (TIL) and cerebrovascular reactivity.
Methods Using the Collaborative European Neuro Trauma Effectiveness Research in TBI (CENTER-TBI) high-resolution
intensive care unit (ICU) cohort, we derived pressure reactivity index (PRx) as the moving correlation coefficient between
slow-wave in ICP and mean arterial pressure, updated every minute. Mean daily PRx, and daily % time above PRx of 0 were
calculated for the first 7 days of injury and ICU stay. This data was linked with the daily TIL-Intermediate scores, including total
and individual treatment sub-scores. Daily mean PRx variable values were compared for each TIL treatment score via mean,
standard deviation, and the Mann U test (Bonferroni correction for multiple comparisons). General fixed effects and mixed
effects models for total TIL versus PRx were created to display the relation between TIL and cerebrovascular reactivity.
Results A total of 249 patients with 1230 ICU days of high frequency physiology matched with daily TIL, were assessed. Total
TIL was unrelated to daily PRx. Most TIL sub-scores failed to display a significant relationship with the PRx variables. Mild
hyperventilation (p < 0.0001), mild hypothermia (p = 0.0001), high levels of sedation for ICP control (p = 0.0001), and use
vasopressors for CPP management (p < 0.0001) were found to be associated with only a modest decrease in mean daily PRx
or % time with PRx above 0.
Conclusions Cerebrovascular reactivity remains relatively independent of intracranial hypertension therapeutic intensity, sug-
gesting inadequacy of current TBI therapies in modulating impaired autoregulation. These findings support the need for
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investigation into the molecular mechanisms involved, or individualized physiologic targets (ICP, CPP, or Co2) in order to treat
dysautoregulation actively.
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Introduction
Impaired cerebrovascular reactivity after traumatic brain injury
(TBI) has emerged as a meaningful independent factor associated
with mortality and poor functional outcome at 6 and 12 months
post-injury [5, 20, 27, 28]. Current methodology for continuous
measurement of cerebrovascular reactivity employed in the inten-
sive care unit (ICU) is based on calculation of amoving correlation
between slow-wave vasogenic fluctuations pulsatile cerebral blood
volume (using the surrogate of intracranial pressure (ICP)), and a
measure of driving pressure (such as mean arterial pressure
(MAP)) [5, 26].
The pressure reactivity index (PRx), derived from ICP and
MAP, is the most commonly quoted index of cerebrovascular
reactivity in the TBI literature [26]. This particular index has
experimental support as a potential measure of the lower limit
of autoregulation [3]. Further, in adult TBI, PRx has defined
critical thresholds associated with poor outcomes [20, 27].
However, despite the strong relationship between autoregula-
tion and outcome, currently available ICU therapies do not allow
us tomodulate cerebrovascular reactivity as a pathway to improv-
ing outcome. A recent retrospective analysis assessed the last
25 years of experience with therapies guided by cerebral physiol-
ogymonitoring in adult TBI. This analysis suggested that, despite
changes in Brain Trauma Foundation (BTF) ICP and cerebral
perfusion pressure (CPP) targets, little to no impact on PRx was
seen [7]. This limited change in monitored PRx occurred in par-
allel to a stable mortality level in the same cohort over the 25-year
period. This corroborates similar findings from a smaller study of
48 TBI patients, evaluating factors impacting the ability to calcu-
late CPP optimum from PRx [24]. While these findings suggest
that PRx is independent of current TBI therapies, they require
robust corroboration in an analysis that accounts for the intensity
of therapy. If validated, they suggest the need for further work on
the molecular mechanisms or complex individual physiology in-
volved in impaired cerebrovascular reactivity, so as to aid in the
development of targeted therapies aimed at enhancing
autoregulatory reserve, with the aim of increasing resilience to
physiological insults and improving outcomes.
The goal of this project was to assess the association between
daily treatment intensity, as measured through the therapeutic
intensity level (TIL) intermediate scoring system [12, 31], and
daily measures of cerebrovascular reactivity, using the
Collaborative European Neuro Trauma Effectiveness Research
in TBI (CENTER-TBI) study high-resolution ICU sub-study
cohort [13].
Methods
Patient population
All patients from the multi-center CENTER-TBI high-
resolution ICU cohort were included for this study. These
patients were prospectively recruited between January 2015
and December 2017, from 21 centers in the European Union
(EU). All patients were admitted to ICU for their TBI during
the course of the study, with high-frequency digital signals
recorded from their ICU monitors during the course of their
ICU stay. All patients suffered predominantly from moderate
to severe TBI (moderate = Glasgow Coma Score (GCS) 9 to
12, and severe = GCS of 8 or less). A minority of patients
suffered from non-severe TBI, with subsequent early deterio-
ration leading to ICU admission for care and monitoring. All
patients in this cohort had invasive ICP monitoring conducted
in accordance with the BTF guidelines [4].
EthicsData used in these analyses were collected as part of the
CENTER-TBI study which had individual national or local
regulatory approval; the UK Ethics approval is provided as an
exemplar (IRAS No. 150943; REC 14/SC/1370). The
CENTER-TBI study (EC grant 602150) has been conducted
in accordance with all relevant laws of the EU if directly
applicable or of direct effect and all relevant laws of the coun-
try where the recruiting sites were located, including but not
limited to, the relevant privacy and data protection laws and
regulations (the “Privacy Law”), the relevant laws and regu-
lations on the use of human materials, and all relevant guid-
ance relating to clinical studies from time to time in force
including, but not limited to, the ICH Harmonised Tripartite
Guideline for Good Clinical Practice (CPMP/ICH/135/95)
(“ICH GCP”) and the World Medical Association
Declaration of Helsinki entitled “Ethical Principles for
Medical Research Involving Human Subjects”. Informed con-
sent by the patients and/or the legal representative/next of kin
was obtained, accordingly to the local legislations, for all pa-
tients recruited in the core dataset of CENTER-TBI and doc-
umented in the e-CRF.
Data collection
As part of recruitment to the multi-center high-resolution ICU
cohort of CENTER-TBI [13], demographics and clinical data
were prospectively collected and had high-frequency digital
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signals from ICU monitoring recorded throughout their ICU
stay, with the goal of initiating recording within 24 h of injury.
All digital ICU signals were further processed (see signal
acquisition/signal processing). For the purpose of this study,
the following admission demographic variables were collect-
ed: age, sex, and admission Glasgow Coma Scale (GCS, total
and motor). Finally, daily total TIL and all daily TIL sub-
scores were also collected for each patient for the first 7 days
after injury. Of note, not all patients had a full 7 days of TIL
scoring given different clinical trajectories. Appendix A pro-
vides a breakdown of the TIL intermediate scoring system and
its sub-score components. CENTER-TBI data version 1.0 was
accessed for the purpose of this study, via Opal database soft-
ware [6].
Signal acquisition
Arterial blood pressure (ABP) was obtained through either
radial or femoral arterial lines connected to pressure transduc-
ers. ICP was acquired via an intra-parenchymal strain gauge
probe (Codman ICP MicroSensor; Codman & Shurtleff Inc.,
Raynham, MA), parenchymal fiber optic pressure sensor
(Camino ICP Monitor, Integra Life Sciences, Plainsboro, NJ,
USA; https://www.integralife.com/) or external ventricular
drain. All signals were recorded using digital data transfer or
digitized via an A/D converter (DT9801; Data Translation,
Marlboro, MA), where appropriate, sampled at frequency of
100 Hz (Hz) or higher, using the ICM+ software (Cambridge
Enterprise Ltd., Cambridge, UK; http://icmplus.neurosurg.
cam.ac.uk) or Moberg CNS Monitor (Moberg Research Inc.,
Ambler, PA, USA) or a combination of both. Signal artifacts
were removed using automated methods prior to further
processing or analysis.
Signal processing
Post-acquisition processing of the above signals was conduct-
ed using ICM+. CPP was determined as CPP =MAP − ICP.
Ten-second moving averages (updated every 10 s to avoid
data overlap) were calculated for all recorded signals: ICP,
ABP (which produced MAP), and CPP.
PRx was derived using the Pearson correlation between 30
consecutive 10 s mean values for ICP and MAP, updated
every minute. Data were provided in minute-by-minute
comma-separated variable sheets for the entire duration of
recording for each patient.
Data processing
Post-ICM+ processing was undertaken using R (R Core Team
(2016). R: A language and environment for statistical comput-
ing. R Foundation for Statistical Computing, Vienna, Austria.
URL https://www.R-project.org/). Using the date and time
stamp for each minute-by-minute data point, daily summaries
were provided for days 1 through 7 after injury for each pa-
tient, producing daily mean ICP, daily % time with ICP above
20 mmHg, daily % time with ICP above 22 mmHg, daily
mean PRx, and daily % time spent above PRx of 0. This
PRx threshold was selected given previous literature
confirming its relationship with global patient outcome [20],
and belief that is represents the PRx value where vascular
reactivity begins becoming impaired [3], representing phase-
shift between slow-waves in ICP and MAP trending below
90°. These daily physiologic measures were then linked with
the daily TIL measures for statistical analysis. These data are
referred to as the “day-matched” data.
A second data sheet was also produced using time-shifted
data. We were interested in assessing the impact of TIL score
on the following-day cerebrovascular reactivity. As such, we
time-shifted the TIL and physiology data in order to assess this
relationship. We refer to this data as the “time-shifted” data.
Statistics
All statistical analysis was conducted using R and XLSTAT
(Addinsoft, New York, NY; https://www.xlstat.com/en/) add-
on package to Microsoft Excel (Microsoft Office 15, Version
16.0.7369.1323). Normality of continuous variables was
assessed via the Shapiro-Wilks test.
Box plots were used to visualize the relationship between
ICP and PRx variables across increasing TIL total and sub-
scores. Using total TIL score, mean ICP, and PRx variable
values were compared across increasing TIL, using the
Jonckheere-Terpstra test, with 1000 permutations, with alpha
set at 0.05 for this test. Similarly, mean PRx variable values
were compared across each TIL sub-score, with alpha set at
0.0005 after the Bonferroni correction for multiple compari-
sons. Given that almost all TIL sub-scores failed to demon-
strate statistical significance in association with PRx variables,
only the statistically significant associations are reported in
detail in the manuscript. Identical results were found for mean
daily PRx, and mean daily % time above PRx of 0. Similarly,
identical results were found for both the day-matched and
time-shifted data sheets.
In order to highlight the association between cerebrovascu-
lar reactivity with therapeutic intensity, we derived both gen-
eral linear fixed effects and linear mixed effects (LME)
models for total TIL versus: mean daily PRx and daily % time
with PRx above 0. Patient examples were used to confirm no
autocorrelation between daily physiologic measures, using
autocorrelation function (ACF) and partial autocorrelation
function (PACF) plots. Thus, no autocorrelative structure for
the PRx variables was included in these models. Both the
generalized and LME models were to be compared for
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superiority via the Akaike information criterion (AIC), the
Bayesian information criterion (BIC), and analysis of variance
(ANOVA). Alpha for ANOVA testing was set at 0.05. Given
all LME and generalized fixed effects models failed to reach
significance for the relationship between total TIL and cere-
brovascular reactivity metrics, these models are not reported
in detail within the manuscript, and only mentioned in refer-
ence to the global findings of this study.
Finally, in order to determine if there is a difference in
response of PRx measures to TIL therapies during the more
acute initial phase of ICU stay, we evaluated all of the above in
the first 3 days of recording. Of note, none of the results were
different using the first 3 days, versus the first 7 days of ICU
stay. As such, we report only the first 7 days of ICU stay
within this manuscript, making reference to the first 3 days
analysis intermittently throughout.
Results
Patient demographics
There were 249 patients from the CENTER-TBI high-resolu-
tion ICU cohort, for whom high-frequency physiologic sig-
nals and daily TIL scores were available, and were included in
this study. An account of general patient characteristics can be
found in other publications on this high-resolution data cohort
[28, 29]. A total of 1230 daily observations of TIL and daily
PRx variables were used for this analysis. The mean age was
46.8 ± 18.9 years, with 198 being male. Median admission
GCS was 6 (IQR, 3 to 10), median admission GCS motor
score was 4 (IQR, 1 to 5), and median duration of physiologic
monitoring was 140.6 h (IQR, 94.4 to 213.6). All continuous
variables were found to be non-parametrically distributed.
Mean daily ICP and PRx variable values across the patient
population remained relatively constant, with mean daily ICP
well below BTF defined thresholds and mean daily % time
with PRx above 0 remaining consistently above 40 to 50%.
There was only a significant drop in % time with PRx above
zero going from day 1 (i.e., first 24 h after injury) to day 2
post-injury (p = 0.03; MannU), and going from day 2 to day 3
(p = 0.004; Mann U), with no difference between days 3 and
7. A similar relationship was seen for % time with ICP above
20 mmHg, % time with ICP above 22 mmHg. Figure 1 dis-
plays boxplots for the mean daily ICP and mean daily % time
with PRx above 0.
Daily total TIL and cerebrovascular reactivity
Comparing total daily TIL to the daily measures of ICP and
PRx, the same relationships were seen for the day-matched
and time-shifted data, using both the first 7 days and first
3 days of data. With increasing total daily TIL, there was an
increase in daily mean ICP, % time above ICP of 20 mmHg
and % time above ICP of 22 mmHg (p = 0.001 on Jonckheere
Terpstra testing for increasing values in all); in keeping with
escalating daily therapy for increasing daily ICP measures. In
contrast, there was no relationship between increasing daily
total TIL and daily measures of PRx (mean values or % time
above threshold; p > 0.05 on Jonckheere-Terpstra test for in-
creasing and decreasing values for all), in both the day-
matched and time-shifted data sheets. This suggests potential-
ly limited treatment effect of daily TIL measured therapies on
daily cerebrovascular reactivity metrics. Figure 2 displays the
boxplots of total daily TIL and both daily % time with PRx
above 0 and mean daily ICP, for both the day-matched and
time-shifted data.
Generalized and LME models were created to assess the
relationship between total TIL and mean daily PRx and daily
% time with PRx above 0. All models failed to display statis-
tically significant relationships with total TIL, even with the
introduction of random effects to both the intercept and gra-
dient by patient (p < 0.05 for all). As such these models will
not be reported further here, but provide confirmatory evi-
dence for the lack of association between TIL and cerebrovas-
cular reactivity metrics.
Daily TIL sub-scores and cerebrovascular reactivity
Comparing daily TIL sub-scores to daily measures of PRx,
identical relationships were seen for all PRx variables (i.e.
,mean PRx, % time with PRx > 0), in both the day-matched
and time-shifted datasets, using both the first 7 days and first
3 days of data. Only 4 daily TIL sub-score measures displayed
a statistically significant decrease in daily PRxmeasures using
day-matched and time-shifted data on Mann U testing: mild
hyperventilation (PaCO2 35 to 40 mmHg), mild hypothermia
(core temp > 35 °C), high sedation levels targeting ICP, and
vasopressor therapy targeting CPP goals. Table 1 provides the
Mann U testing for % time with PRx above 0 for the 4 daily
TIL sub-scores for both the day-matched and time-shifted
data. Appendix B provides the boxplots for both the time-
matched and time-shifted data. Of note, the overall absolute
reduction in daily % time with PRx above 0 seen with these 4
interventions was less than 10%, indicating a modest potential
treatment.
Discussion
The analysis of the relationship between TIL and measures of
cerebrovascular reactivity provided some interesting results
which deserve highlighting. First, evaluating the % time spent
with PRx above zero across the first 7 days of ICU stay, it can
be seen that a large portion of any given day is spent with
impaired cerebrovascular reactivity. There is statistically
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significant decrease in this value going from the first 24 h post
injury to day 2 and day 3 in our cohort. However, from day 3
onwards, there is little change in the amount of time spent with
PRx above zero, with no difference between days. As
discussed below, this initial drop in time above PRx of zero
is not accounted for in total TIL or specific TIL-based
measures, and likely represents the initial spike in impaired
cerebrovascular reactivity after the primary insult, which then
improves spontaneously over the next 48 h of ICU care. With
that said, the TIL metrics provided are course measures of
therapeutic intensity with documentation daily in our data
set. It is unknown if more frequent intervention measures,
Fig. 2 Boxplots of mean daily ICP and mean daily % time with PRx > 0
versus daily total TIL. ICP, intra-cranial pressure; MAP, mean arterial
pressure; mmHg, millimeter of mercury; NS, non-significant; TIL,
therapeutic intensity level; TTIL, total daily TIL. *p values reported are
for the Jonckheere-Terpstra test for increasing mean values. Relationship
between % time and PRx > 0 was non-significant for both increasing and
decreasing mean values. Plot of mean daily % time with PRx above 0
versus daily TTIL a; Plot of mean daily ICP versus daily TTIL b; Plot of
mean daily % time with PRx above 0 versus daily TTIL for time-shifted
data c; Plot of mean daily ICP versus daily TTIL for time-shifted data d
Fig. 1 Boxplots of mean daily ICP and % time with PRx > 0 versus day.
ICP, intra-cranial pressure; MAP, mean arterial pressure; mmHg,
millimeter of mercury; PRx, pressure reactivity index (moving
correlation between ICP and MAP). Day from injury (i.e., day-matched
data), day 1 = day of injury. Plot of daily % time with PRx > 0 versus day
from injury to day-matched data a; Plot of mean daily ICP versus day
from injury to day-matched data b
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perhaps accurately marked in the high-frequency physiology
data, would provide stronger associations with changes in
PRx metrics over time. Recent literature supports variance in
mean PRx response after TBI, with those displaying positive
global outcomes having a more rapid decline in PRx during
the initial ICU days of care [22]. Thus, future analysis of the
impact of therapeutic measures on cerebrovascular reactivity
will not only benefit from high-resolution treatment data, but
also various sub-group analyses based on age, sex, co-mor-
bidities, injury pattern/burden, and patient global outcome.
Such analyses will require large multi-center data sets to ac-
complish these goals.
Second, therapeutic intensity as measured through the total
TIL score has little relationship with cerebrovascular reactiv-
ity, either in an analysis of contemporaneous data, or when lag
effects are explored in time-shifted TIL data. This was also
confirmed using the first 7 days and first 3 days of data,
displaying identical results, indicating no difference between
the entire ICU stay versus the initial acute 72 h. These results
were exemplified by the lack of statistically significant gener-
alized and LME modeling between TTIL and all cerebrovas-
cular reactivity metrics. This is an important finding, which
suggests that overall, current ICU-based treatment strategies
for TBI essentially have limited impact on cerebrovascular
reactivity. This corroborates the findings of Donnelly et al.
in a large single center retrospective cohort of over 1000
TBI patients, where despite changes in BTF-based ICP and
CPP targets, little change in PRx or outcome was seen over
25 years [7].
Third, daily TIL sub-scores for most individual interven-
tions failed to show any significant relationship with the PRx
metrics we explored. Only four daily TIL sub-score parame-
ters were found to be associated with lower mean daily PRx
and daily % time with PRx above 0. These included mild
hyperventilation, mild hypothermia, high levels of sedation
for ICP therapy, and vasopressor usage to target CPP. These
results were similar for both the day-matched and time-shifted
data sheets. Of note, the absolute reduction in % time with
PRx above 0 was only modest for these 4 treatments, with less
than 10% reduction. This highlights that the majority of cur-
rently applied therapies for TBI have limited impact on cere-
brovascular reactivity. With that said, it must be acknowl-
edged that given the strong link between impaired cerebrovas-
cular reactivity and global patient outcome documented in
various patient series [5, 7, 20, 28, 29], even small changes
in vascular reactivity metrics related to current TBI therapies
may carry important implications for mortality and morbidity.
It is still unclear how much of an improvement in PRx, or
other cerebrovascular reactivity metrics, is required in order
to leave a demonstrable impact of patient global outcome.
Thus, despite the majority of TIL-measured therapies failing
to demonstrate a significant change in PRx in this study, those
interventions which had an impact may carry an important
role moving forward in the initial modulation of cerebrovas-
cular reactivity. Further to this, patient sub-group analysis
based on injury pattern, injury burden, and age may play a
role in individual patient response to current TBI therapies. As
such, one should not walk away from this current work think-
ing “all is lost” regarding the impact of current TBI treatments
on cerebrovascular reactivity. Much further work in this area
is required.
Fourth, mild hyperventilation appeared to be associated
with reduced mean daily PRx and daily % time with PRx
above 0. This is in keeping with the literature body supporting
improved vascular reactivity with mild hyperventilation [15,
16, 18]. However, more intensive daily hyperventilation, as
assessed via other daily TIL sub-score measures (i.e., PaCO2
< 35 mmHg), failed to display any relationship with cerebro-
vascular reactivity [16]. This requires further investigation
using treatment data with higher temporal resolution.
Table 1 Mean daily % time with PRx > 0, the Mann U testing for significant TIL sub-scores
TIL sub-score Day-matched data Mann U p value Time-shifted data Mann U p value
Mean (± SD) daily % time with PRx > 0 Mean (± SD) daily % time with PRx > 0
No intervention Intervention No intervention Intervention
Fluid (vasopressors) 57.7 (23.0) 49.5 (24.0) 2.1 × 10−8 57.0 (23.2) 47.8 (23.4) 1.7 × 20−8
Hyperventilation (mild) 55.7 (24.6) 48.0 (22.6) 2.5 × 10−8 54.5 (24.6) 46.3 (22.1) 5.8 × 10−8
Hypothermia (mild) 52.8 (24.0) 44.5 (22.4) 0.0001 51.1 (23.9) 43.5 (21.0) 0.001
Sedation (High) 54.2 (23.4) 49.0 (24.4) 0.0001 53.4 (23.5) 46.7 (23.5) 1.1 × 10−6
CPP, cerebral perfusion pressure; ICP, intra-cranial pressure; MAP, mean arterial pressure; PRx, pressure reactivity index (correlation between slow-
waves in ICP and MAP); SD, standard deviation; TIL, therapeutic intensity level. This table reports p values from the Mann U testing, comparing mean
daily% time above PRx of 0 for specific TIL sub-scores. This table reports both the day-matched data sheet and the time-shifted data sheet, evaluating the
difference in mean values between those receiving a specific intervention vs. those who did not. *Note: p values are bolded for statistical significance
after the Bonferroni correction. TIL fluid (vasopressor) refers to the need for vasopressor therapy to maintain CPP goals. TIL hyperventilation (mild)
refers to mild hypocapnia for ICP control (PaCO2 = 35 to 40 mmHg). TIL hypothermia (mild) refers to cooling to no lower than 35 °C. TIL sedation
(high) refers to high sedation levels aimed at ICP control, but not burst suppression
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However, the lack of association with cerebrovascular reactiv-
ity in the setting of more intensive hyperventilation may be
secondary to exhaustion of the cerebrovascular reserve with
such intensive reduction in CO2 levels [16].
Fifth, mild hypothermia (i.e., core temp 35–36.5 °C) was
associated with a modest reduction in mean daily PRx and
daily percentage of time above PRx of 0, with more intensive
hypothermia therapy (i.e., core temp below 35 °C) not being
associated with vascular reactivity in this cohort. Stable/
improved cerebral autoregulatory capacity is known to occur
with hypothermia therapy [2, 10, 11]. However, experimental
models [8, 9, 23], indicate that moderate to severe degrees of
hypothermia can lead to loss of cerebrovascular reactivity.
This may account for the lack of association between PRx
variables and more intensive measures of hypothermia mea-
sures through other TIL sub-score metrics. This intimate rela-
tion between core and brain temperature requires further in-
vestigation using continuously measured cerebrovascular
reactivity.
Sixth, high levels of sedation for ICP control were associ-
ated with a modest decrease in daily mean PRx and daily %
time above PRx of 0. This likely represents a treatment effect
on ICP, and subsequently CPP, with CPP values being obtain-
ed closer to the optimal CPP value [1, 17, 21]. However,
sedation aimed at burst suppression, as assessed via a separate
TIL sub-score value, was not associated with a change in PRx
metrics. This may reflect injury/disease severity, or reflect the
impairment in cerebrovascular reactivity seen with burst sup-
pression in other patient cohorts using various anesthetic
agents [19, 25]. Further analysis of this relationship between
sedative levels and cerebrovascular reactivity is required,
using higher resolution data.
Seventh, the use of vasopressors to target CPP was also
associated with a modest decrease in mean daily PRx and
daily percentage of time with PRx above 0. This likely reflects
improved CPP targeting with vasopressors and avoiding CPP
values below optimal CPP metrics. However, the impact of
vasoactive compounds on cerebrovascular reactivity after TBI
is still unclear, with many leading to vasoconstrictive states in
experimental models [14], and requires future investigation
using high temporal resolution vasopressor dosing data linked
with high-frequency physiology in time-series.
Finally, the overall daily time spent with PRx above 0 was
40% or higher for all days, during the first 7 days after injury.
This highlights the unchanged burden of impaired cerebrovas-
cular reactivity after TBI, despite ongoing active ICP and CPP
treatment. It further raises the questions of the role for indi-
vidualized physiologic targets in TBI care, such as those
posed by individual CPP optimum therapy [1, 17, 21], which
is currently under prospective evaluation. Overall, this moti-
vates further investigation into the molecular mechanisms in-
volved in impaired cerebrovascular reactivity after TBI. Such
analysis will require the integration of protein biomarkers with
genetic profiling [30], in order to determine potential mecha-
nisms driving impaired cerebrovascular reactivity. It is
through such techniques that therapies directed at prevention
and treatment may be developed, potentially leading to im-
proved morbidity and mortality in TBI.
Limitations
The overall patient numbers with outcome and basic demo-
graphics were low at 249. This high-resolution cohort was a
small specialty sub-cohort within the larger CENTER-TBI
data collection scheme. This particular cohort of patients is
unique in providing both high-frequency physiologic data
and daily TIL scores during the acute phase of ICU stay,
starting from the day of injury. Similar data will be needed
to replicate our results, and more detailed assessments of the
impact of interventions on autoregulatory efficiency will re-
quire therapy data with higher temporal resolution of treat-
ment characteristics, such as TIL/TIL sub-scores, vasopressor
dosing, and sedation dosing.
Furthermore, the impact of mild hyperventilation, mild hy-
pothermia, high sedation levels, and vasopressor usage is still
unclear. The impact on PRx metrics was modest at best in this
analysis. Future studies require higher frequency data collec-
tion for TIL, core temperature, brain temperature, sedation
dosing, and vasopressor dosing, in order to determine if any
temporal response is seen between these treatments and cere-
brovascular reactivity.
It must be acknowledged that TIL scores, and sub-scores,
are relatively gross measures of therapeutic intensity. As such,
despite failing to demonstrate a strong statistical significance
with daily vascular reactivity metrics, therapeutic intensity
measures captured at a higher temporal frequency, with more
detailed annotations linked with the real-time physiology, may
demonstrate an association with vascular reactivity measures.
As such, the results of this study should be considered prelim-
inary. Further studies are planned to evaluate the association
between vascular reactivity, ICP, CPP, and other cerebral
physiologic measures, using time-series physiology data with
detailed treatment annotations.
Finally, in such a small data set, with various TIL-based
treatment metrics measured, sometimes with very few patients
have specific interventions, it raises the question of potential
false-positive or false-negative results. We attempted to ac-
count for such false statistical positives through alpha correc-
tion using the Bonferonni methodology, only report results as
significant with a p value of less than 0.0005. As such, the
positive results reported, we feel are likely true positives.
However, the significant reported TIL sub-scores were
amongst the main drivers of overall TIL in our cohort (as
seen in Appendix C). Thus, the overall significant association
with PRx metrics may just be a reflection of these aspects
being reported more frequently. In parallel, with such a small
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data set and large number of treatment variables, with a strict
corrected alpha of 0.0005, there exists the potential that some
of the negative results may be false-negatives. As such, we
emphasize the preliminary nature of our results here, and high-
light the need for larger future studies with higher frequency
treatment data. The results within this manuscript should be
considered exploratory only at this time.
Given all the highlighted limitations, the results of this
study should be considered preliminary, despite corroborating
the previous retrospective work in the literature [7].
Conclusions
Cerebrovascular reactivity remains relatively independent of
therapeutic intensity, suggesting inadequacy of current TBI
therapies in modulating impaired autoregulation. These find-
ings provide support for prior preliminary retrospective find-
ings, and support the need for investigation into the molecular
mechanisms involved in order to develop therapies aimed at
prevention and treatment.
Acknowledgments CENTER-TBI high resolution sub-study participants
and investigators: Audny Anke, Department of Physical Medicine and
Rehabilitation, University hospital Northern Norway; Ronny Beer,
Department of Neurology, Neurological Intensive Care Unit, Medical
University of Innsbruck, Innsbruck, Austria; Bo-Michael Bellander,
Department of Neurosurgery & Anesthesia & intensive care medicine,
Karolinska University Hospital, Stockholm, Sweden; Andras Buki,
Department of Neurosurgery, University of Pecs and MTA-PTE
Clinical Neuroscience MR Research Group and Janos Szentagothai
Research Centre, University of Pecs, Hungarian Brain Research
Program, Pecs, Hungary; Giorgio Chevallard, NeuroIntensive Care,
Niguarda Hospital, Milan, Italy; Arturo Chieregato, NeuroIntensive
Care, Niguarda Hospital, Milan, Italy; Giuseppe Citerio, NeuroIntensive
Care Unit, Department of Anesthesia & Intensive Care, ASST di Monza,
Monza, Italy; and School of Medicine and Surgery, Università Milano
Bicocca, Milano, Italy; Endre Czeiter, Department of Neurosurgery,
University of Pecs and MTA-PTE Clinical Neuroscience MR Research
Group and Janos Szentagothai Research Centre, University of Pecs,
Hungarian Brain Research Program (Grant No. KTIA 13 NAP-A-II/8),
Pecs, Hungary; Bart Depreitere, Department of Neurosurgery, University
Hospitals Leuven, Leuven, Belgium; George Eapen †, Shirin Frisvold,
Department of Anesthesiology and Intensive Care, University Hospital
Northern Norway, Tromso, Norway; Raimund Helbok, Department of
Neurology, Neurological Intensive Care Unit, Medical University of
Innsbruck, Innsbruck, Austria; Stefan Jankowski, Neurointensive Care,
Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK;
Danie l Kondzie l la , Depar tments of Neurology, Cl in ica l
Neurophysiology and Neuroanesthesiology, Region Hovedstaden
Rigshospitalet, Copenhagen, Denmark; Lars-Owe Koskinen,
Department of Clinical Neuroscience, Neurosurgery, Umea University
Hospital, Umea, Sweden; Geert Meyfroidt, Intensive Care Medicine,
University Hospitals Leuven, Leuven, Belgium; Kirsten Moeller,
Department Neuroanesthesiology, Region Hovedstaden Rigshospitalet,
Copenhagen, Denmark; David Nelson, Department of Neurosurgery &
Anesthesia & intensive care medicine, Karolinska University Hospital,
Stockholm, Sweden; Anna Piippo-Karjalainen, Helsinki University
Central Hospital, Helsinki, Finland; Andreea Radoi, Department of
Neurosurgery, Vall d’Hebron University Hospital, Barcelona, Spain;
Arminas Ragauskas, Department of Neurosurgery, Kaunas University
of technology and Vilnius University, Vilnius, Lithuania; Rahul Raj,
Helsinki University Central Hospital, Helsinki, Finland; Jonathan
Rhodes, Department of Anaesthesia, Critical Care & Pain Medicine
NHS Lothian & University of Edinburg, Edinburgh, UK; Saulius
Rocka, Department of Neurosurgery, Kaunas University of technology
and Vilnius University, Vilnius, Lithuania; Rolf Rossaint, Department of
Anaesthesiology, University Hospital of Aachen, Aachen, Germany;
Juan Sahuquillo, Department of Neurosurgery, Vall d’Hebron
University Hospital, Barcelona, Spain; Oliver Sakowitz, Klinik für
Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany;
Department of Neurosurgery, University Hospital Heidelberg,
Heidelberg, Germany; Ana Stevanovic, Department of Anaesthesiology,
University Hospital of Aachen, Aachen, Germany; Nina Sundström,
Department of Radiation Sciences, Biomedical Engineering, Umea
University Hospital, Umea, Sweden; Riikka Takala, Perioperative
Services, Intensive Care Medicine, and Pain Management, Turku
University Central Hospital and University of Turku, Turku, Finland;
Tomas Tamosuitis, Neuro-intensive Care Unit, Kaunas University of
Health Sciences, Kaunas, Lithuania; Olli Tenovuo, Rehabilitation and
Brain Trauma, Turku University Central Hospital and University of
Turku, Turku, Finland; Peter Vajkoczy, Neurologie, Neurochirurgie und
Psychiatrie, Charité–Universitätsmedizin Berlin, Berlin, Germany;
Alessia Vargiolu, NeuroIntensive Care Unit, Department of Anesthesia
& Intensive Care, ASST di Monza, Monza, Italy; Rimantas Vilcinis,
Department of Neurosurgery, Kaunas University of Health Sciences,
Kaunas, Lithuania; Stefan Wolf, Interdisciplinary Neuro Intensive Care
Unit, Charité–Universitätsmedizin Berlin, Berlin, Germany; Alexander
Younsi, Department of Neurosurgery, University Hospital Heidelberg,
Heidelberg, Germany.
Funding Data used in preparation of this manuscript were obtained in the
context of CENTER-TBI, a large collaborative project with the support of
the European Union 7th Framework program (EC grant 602150).
Additional funding was obtained from the Hannelore Kohl Stiftung
(Germany), from OneMind (USA) and from Integra LifeSciences
Corporation (USA).
DKM was also supported by funding from the National
Institute for Health Research (NIHR, UK) through a Senior
Investigator award and the Cambridge Biomedical Research
Centre at the Cambridge University Hospitals NHS Foundation
Trust. The study also received additional support from the NIHR
Clinical Research network. The views expressed are those of the
authors and not necessarily those of the NHS, the NIHR or the
Department of Health and Social Care, UK.
FAZ has received salary support for dedicated research time, during
which this project was completed. FAZ receives research support from the
University of Manitoba Thorlakson Chair in Surgical Research
Establishment Fund, the University of Manitoba VPRI Research
Investment Fund (RIF), the University of Manitoba Rudy Falk
Clinician-Scientist Professorship, and the Health Sciences Centre
Foundation Winnipeg.
Compliance with ethical standards
Conflict of interest Data used in preparation of this manuscript were
obtained in the context of CENTER-TBI, a large collaborative project
with the support of the European Union 7th Framework program (EC
grant 602150). Additional funding was obtained from the Hannelore
Kohl Stiftung (Germany), from OneMind (USA), and from Integra
LifeSciences Corporation (USA).
PS and MC receive part of licensing fees for the software ICM+
(Cambridge Enterprise Ltd., UK) used for data collection and analysis
in this study.
1962 Acta Neurochir (2019) 161:1955–1964
Ethical approval All procedures performed in studies involving human
participants were in accordance with the ethical standards of the institu-
tional and/or national research committee (name of institute/committee)
and with the 1964 Helsinki declaration and its later amendments or com-
parable ethical standards.
Data used in these analyses were collected as part of the CENTER-
TBI study which had individual national or local regulatory approval; the
UKEthics approval is provided as an exemplar: (IRASNo. 150943; REC
14/SC/1370). The CENTER-TBI study (EC grant 602150) has been con-
ducted in accordance with all relevant laws of the EU if directly applica-
ble or of direct effect and all relevant laws of the country where the
recruiting sites were located, including but not limited to, the relevant
privacy and data protection laws and regulations (the “Privacy Law”),
the relevant laws and regulations on the use of human materials, and all
relevant guidance relating to clinical studies from time to time in force
including, but not limited to, the ICHHarmonised Tripartite Guideline for
Good Clinical Practice (CPMP/ICH/135/95) (“ICH GCP”) and theWorld
Medical Association Declaration of Helsinki entitled “Ethical Principles
for Medical Research Involving Human Subjects.” Informed consent by
the patients and/or the legal representative/next of kin was obtained, ac-
cordingly to the local legislations, for all patients recruited in the core
dataset of CENTER-TBI and documented in the e-CRF.
Informed consent Informed consent was obtained from all individual
participants included in the study. Informed consent by the patients and/or
the legal representative/next of kin was obtained, accordingly to the local
legislations, for all patients recruited in the core dataset of CENTER-TBI
and documented in the e-CRF.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
1. Aries MJH, Czosnyka M, Budohoski KP et al (2012) Continuous
determination of optimal cerebral perfusion pressure in traumatic
brain injury. Crit Care Med 40(8):2456–2463
2. Bisschops LLA, Hoedemaekers CWE, Simons KS, van der Hoeven
JG (2010) Preserved metabolic coupling and cerebrovascular reac-
tivity during mild hypothermia after cardiac arrest. Crit Care Med
38(7):1542–1547
3. Brady KM, Lee JK, Kibler KK, Easley RB, Koehler RC, Shaffner
DH (2008) Continuous measurement of autoregulation by sponta-
neous fluctuations in cerebral perfusion pressure: comparison of 3
methods. Stroke 39(9):2531–2537
4. Carney N, Totten AM, O’Reilly C et al (2017) Guidelines for the
management of severe traumatic brain injury, Fourth Edition.
Neurosurgery 80(1):6–15
5. Czosnyka M, Smielewski P, Kirkpatrick P, Laing RJ, Menon D,
Pickard JD (1997) Continuous assessment of the cerebral vasomo-
tor reactivity in head injury. Neurosurgery 41(1):11–17 discussion
17–19
6. Doiron D,Marcon Y, Fortier I, Burton P, Ferretti V (2017) Software
application profile: Opal and Mica: open-source software solutions
for epidemiological data management, harmonization and dissem-
ination. Int J Epidemiol 46(5):1372–1378
7. Donnelly J, Czosnyka M, Adams H et al (2018) Twenty-five years
of intracranial pressure monitoring after severe traumatic brain
injury: a retrospective, single-center analysis. Neurosurgery.
https://doi.org/10.1093/neuros/nyy468
8. Fujita M, Wei EP, Povlishock JT (2012) Effects of hypothermia on
cerebral autoregulatory vascular responses in two rodent models of
traumatic brain injury. J Neurotrauma. 2019 May 15;36(10):1505-
1517. https://doi.org/10.1089/neu.2018.6182
9. Irikura K, Miyasaka Y, Nagai S, Yuzawa I, Morii S, Fujii K (1998)
Moderate hypothermia reduces hypotensive, but not hypercapnic
vasodilation of pial arterioles in rats. J Cereb Blood Flow Metab
18(12):1294–1297
10. Koizumi H, Suehiro E, Fujiyama Y, Yoneda H, Ishihara H, Nomura
S, Fujii M, Suzuki M (2016) Effects of brain temperature on cere-
brovascular autoregulation during the acute stage of severe traumat-
ic brain injury. Acta Neurochir Suppl 122:193–197
11. Lavinio A, Timofeev I, Nortje J et al (2007) Cerebrovascular reac-
tivity during hypothermia and rewarming. Br J Anaesth 99(2):237–
244
12. Maas AIR, Harrison-Felix CL, Menon D et al (2011) Standardizing
data collection in traumatic brain injury. J Neurotrauma 28(2):177–
187
13. MaasAIR,MenonDK, Steyerberg EW, Citerio G, Lecky F,Manley
GT, Hill S, Legrand V, Sorgner A, CENTER-TBI Participants and
Investigators (2015) Collaborative European NeuroTrauma
Effectiveness Research in Traumatic Brain Injury (CENTER-
TBI): a prospective longitudinal observational study.
Neurosurgery 76(1):67–80
14. McCulloch J, Edvinsson L (1984) Cerebrovascular smooth muscle
reactivity: a critical appraisal of in vitro and in situ techniques. J
Cereb Blood Flow Metab 4(2):129–139
15. McCulloch TJ, TurnerMJ (2009) The effects of hypocapnia and the
cerebral autoregulatory response on cerebrovascular resistance and
apparent zero flow pressure during isoflurane anesthesia. Anesth
Analg 108(4):1284–1290
16. Meng L, Gelb AW (2015) Regulation of cerebral autoregulation by
carbon dioxide. Anesthesiology 122(1):196–205
17. Needham E, McFadyen C, Newcombe V, Synnot AJ, CzosnykaM,
Menon D (2017) Cerebral perfusion pressure targets individualized
to pressure-reactivity index in moderate to severe traumatic brain
injury: a systematic review. J Neurotrauma 34(5):963–970
18. Newell DW,Weber JP,Watson R, Aaslid R,WinnHR (1996) Effect
of transient moderate hyperventilation on dynamic cerebral auto-
regulation after severe head injury. Neurosurgery 39(1):35–43 dis-
cussion 43-44
19. Reinsfelt B,Westerlind A, Houltz E, Ederberg S, ElamM, Ricksten
S-E (2003) The effects of isoflurane-induced electroencephalo-
graphic burst suppression on cerebral blood flow velocity and ce-
rebral oxygen extraction during cardiopulmonary bypass. Anesth
Analg 97(5):1246–1250
20. Sorrentino E, Diedler J, Kasprowicz M et al (2012) Critical thresh-
olds for cerebrovascular reactivity after traumatic brain injury.
Neurocrit Care 16(2):258–266
21. Steiner LA, Czosnyka M, Piechnik SK, Smielewski P, Chatfield D,
Menon DK, Pickard JD (2002) Continuous monitoring of cerebro-
vascular pressure reactivity allows determination of optimal cere-
bral perfusion pressure in patients with traumatic brain injury. Crit
Care Med 30(4):733–738
22. Svedung Wettervik T, Howells T, Enblad P, Lewén A (2019)
Temporal neurophysiological dynamics in traumatic brain injury:
role of pressure reactivity and optimal cerebral perfusion pressure
for predicting outcome. J Neurotrauma. https://doi.org/10.1089/
neu.2018.6157
23. Verhaegen MJ, Todd MM, Hindman BJ, Warner DS (1993)
Cerebral autoregulation during moderate hypothermia in rats.
Stroke 24(3):407–414
24. Weersink CSA, Aries MJH, Dias C et al (2015) Clinical and phys-
iological events that contribute to the success rate of finding
Acta Neurochir (2019) 161:1955–1964 1963
“optimal” cerebral perfusion pressure in severe brain trauma pa-
tients. Crit Care Med 43(9):1952–1963
25. Woodcock TE,Murkin JM, Farrar JK, TweedWA, Guiraudon GM,
McKenzie FN (1987) Pharmacologic EEG suppression during car-
diopulmonary bypass: cerebral hemodynamic and metabolic effects
of thiopental or isoflurane during hypothermia and normothermia.
Anesthesiology 67(2):218–224
26. Zeiler FA, Donnelly J, Calviello L, Smielewski P, Menon DK,
Czosnyka M (2017) Pressure autoregulation measurement tech-
niques in adult traumatic brain injury, part II: a scoping review of
continuous methods. J Neurotrauma 34(23):3224–3237
27. Zeiler FA, Donnelly J, Smieleweski P, Menon D, Hutchinson PJ,
Czosnyka M (2018) Critical thresholds of ICP derived continuous
cerebrovascular reactivity indices for outcome prediction in non-
craniectomized TBI patients: PRx, PAx and RAC. J Neurotrauma
35(10):1107–1115
28. Zeiler FA, Ercole A, Cabeleira M, Carbonara M, Stocchetti N,
Menon DK, Smielewski P, Czosnyka M (2018) Comparison of
performance of different optimal cerebral perfusion pressure param-
eters for outcome prediction in adult TBI: a CENTER-TBI study. J
Neurotrauma
29. Zeiler FA, Ercole A, Cabeleira M, Zoerle T, Stocchetti NN, Menon
DK, Smielewski P, Czosnyka M, CENTER-TBI High Resolution
Sub-Study Participants and Investigators (2019) Univariate
comparison of performance of different cerebrovascular reactivity
indices for outcome association in adult TBI: a CENTER-TBI
study. Acta Neurochir. https://doi.org/10.1007/s00701-019-03844-
1
30. Zeiler FA, Thelin EP, Donnelly J, Stevens AR, Smielewski P,
Czosnyka M, Hutchinson PJ, Menon DK (2019) Genetic drivers
of cerebral blood flow dysfunction in TBI: a speculative synthesis.
Nat Rev Neurol 15(1):25–39
31. Zuercher P, Groen JL, Aries MJH, Steyerberg EW, Maas AIR,
Ercole A, Menon DK (2016) Reliability and validity of the therapy
intensity level scale: analysis of clinimetric properties of a novel
approach to assessmanagement of intracranial pressure in traumatic
brain injury. J Neurotrauma 33(19):1768–1774
George Eapen is deceased. This paper is dedicated to his memory.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
Affiliations
Frederick A. Zeiler1,2,3,8,9 & Ari Ercole1 & Erta Beqiri3 & Manuel Cabeleira3 & Marcel Aries4 & Tommaso Zoerle5 &
Marco Carbonara5 & Nino Stocchetti5,6 & Peter Smielewski3 & Marek Czosnyka3,7 & David K. Menon1
1 Division of Anaesthesia, Addenbrooke’s Hospital, University of
Cambridge, Cambridge, UK
2 Department of Surgery, Rady Faculty of Health Sciences, University
of Manitoba, Winnipeg, MB R3A 1R9, Canada
3 Brain Physics Laboratory, Division of Neurosurgery, Department of
Clinical Neurosciences, Addenbrooke’s Hospital, University of
Cambridge, Cambridge, UK
4 Department of Intensive Care, Maastricht UMC,
Maastricht, Netherlands
5 Neuro ICU Fondazione IRCCS Cà Granda Ospedale Maggiore
Policlinico, Milan, Italy
6 Department of Physiopathology and Transplantation, Milan
University, Milan, Italy
7 Institute of Electronic Systems, Warsaw University of Technology,
Warsaw, Poland
8 Department of Human Anatomy and Cell Science, Rady Faculty of
Health Sciences, University of Manitoba, Winnipeg, Canada
9 Department of Biomedical Engineering, Faculty of Engineering,
University of Manitoba, Winnipeg, Canada
1964 Acta Neurochir (2019) 161:1955–1964
